Fingerprint
Dive into the research topics where Irit Avivi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
F.ZajaFrancescoEuropean Mantle Cell Lymphoma Network, 16 May 2026, In: The Lancet. 407, 10542, p. 1953-1967 15 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Can Belantamab mafodotin cause macro LDH?
Hakakian, L., Shragai, T., Trestman, S., Cohen, Y. C., Katz, B. Z., Arafat, N., Hassoun, E., Melamed, N. & Avivi, I., 2026, (Accepted/In press) In: Leukemia and Lymphoma.Research output: Contribution to journal › Article › peer-review
-
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., Jiménez-Ubieto, A., Gangatharan, S. A., Benjamini, O., Thieblemont, C., Tucci, A., Elinder-Camburn, A., Illes, A., Novak, J., Pavlovsky, M. A. & McDonald, A. & 178 others, , 10 Jan 2026, In: The Lancet. 407, 10524, p. 161-173 13 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations
Shpitzer, D., Perry, C., Shragai, T., Melamed, G., Smith, M. R., Vitkon, R., Alapi, H. & Avivi, I., May 2026, In: Cancers. 18, 9, 1471.Research output: Contribution to journal › Article › peer-review
Open Access -
Safety and Efficacy of Talquetamab + Teclistamab In Patients with Relapsed/Refractory Multiple Myeloma from Phase 1B of Redirectt-1: Results with an Extended Median Follow-Up of 3 Years
Ocio, E. M., Mateos, M. V., Magen, H., Gatt, M., Sebag, M., Kim, K., Min, C. K., Yoon, S. S., Chu, M. P., Rodríguez-Otero, P., Avivi, I., Cardé, N. A. Q., Krevvata, M., Henninger, T., Thakkar, P., Festa, M., Huang, L., Zhou, J. X., Takamoto, M. & Pei, L. & 6 others, , Jan 2026, In: Haematologica. 111, p. 38 1 p.Research output: Contribution to journal › Article › peer-review
Open Access